Claims for Patent: 6,825,208

Summary for Patent: 6,825,208

Title:	Tetrahydroquinoline derivatives as antithrombotic agents
Abstract:	This invention relates generally to tetracyclic tetrahydroquinoline compounds, and analogues thereof, and pharmaceutically acceptable salt forms thereof, which are selective inhibitors of serine protease enzymes, especially factor VIIa; pharmaceutical compositions containing the same; and methods of using the same as anticoagulant agents for modulation of the coagulation cascade.
Inventor(s):	Zhou; Jinglan (San Diego, CA), Robinson; Leslie (Del Mar, CA), Gubernator; Nikolaus M. (Del Mar, CA), Saiah; Eddine (LaJolla, CA), Bai; Xu (Carlsbad, CA), Gu; Xin (Scotch Plains, NJ)
Assignee:	Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Application Number:	10/223,860
Patent Claims:	1. A compound of Formula (I): ##STR81## or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein; X is --NH--; ring A, including the two atoms of Ring B to which it is attached, is a phenyl ring; wherein, in addition to R.sup.A, ring A is substituted with 0-3 R.sup.AA ; R.sup.A is selected from: F, Cl, Br, OH, OCH.sub.3, OCH.sub.2 CH.sub.3, OCH(CH.sub.3).sub.2, --OCH.sub.2 CH.sub.2 CH.sub.3, --OCF.sub.3, --CN, --NH.sub.2, --NH.sub.2 NH.sub.3, C(.dbd.NR.sup.1)NR.sup.2 R.sup.3, --NHC(.dbd.NR.sup.1)NR.sup.2 R.sup.3, --NR.sup.2 CH(.dbd.NR.sup.1), --C(O)NR.sup.2 R.sup.3, --S(O).sub.2 NR.sup.2a R.sup.3, --NR.sup.2 R.sup.3, --CH.sub.2 NR.sup.2 R.sup.3, --CH.sub.2 CH.sub.2 NR.sup.2 R.sup.3, --CH(CH.sub.3)NR.sup.2 R.sup.3, --CH.sub.2 CH.sub.2 CH.sub.2 NR.sup.2 R.sup.3, --CH.sub.2 CH(CH.sub.3)NR.sup.2 R.sup.3, --CH(CH.sub.2 CH.sub.3)NR.sup.2 R.sup.3, --CH(CH.sub.3)CH.sub.2 NR.sup.2 R.sup.3, --C(CH.sub.3).sub.2 NR.sup.2 R.sup.3, --(C.sub.1-3 alkyl)CO.sub.2 H, --O--(C.sub.1-3 alkyl)CO.sub.2 H, --S--(C.sub.1-3 alkyl)CO.sub.2 H, --(C.sub.1-3 alkyl)CH(NH.sub.2)CO.sub.2 H, --C(O)NHCH.sub.2 CH.sub.2 NH(C.sub.1-3 alkyl), --C(O)NHCH.sub.2 CH.sub.2 N(C.sub.1-3 alkyl).sub.2, --CH.sub.2 NCOO(C.sub.1-4 alkyl), ##STR82## ##STR83## R.sup.1 is selected from: H, OH, --NH.sub.2, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, phenylCH.sub.2 --, and phenylCH.sub.2 CH.sub.2 --; R.sup.1a, at each occurrence, is selected from: H and C.sub.1-4 alkyl; R.sup.1b is selected from: H, Cl, C.sub.1-4 alkyl, NH.sub.2, and NHNH.sub.2 ; R.sup.1c is selected from: H and C.sub.1-4 alkyl; R.sup.2, at each occurrence, is selected from: H, OH, C.sub.1-6 alkyl, C.sub.1-6 alkylcarbonyl, C.sub.1-4 alkoxycarbonyl, phenyl, phenyl(C.sub.1-3 alkyl)--, C.sub.6-10 aryloxy, C.sub.6-10 aryloxycarbonyl, C.sub.6-10 arylmethylcarbonyl, (C.sub.1-4 alkylcarbonyloxy)C.sub.1-4 alkoxycarbonyl, (C.sub.6-10 arylcarbonyloxy)C.sub.1-4 alkoxycarbonyl, C.sub.1-6 alkylaminocarbonyl, phenylaminocarbonyl, and (phenyl)C.sub.1-4 alkoxycarbonyl; R.sup.2a, at each occurrence, is selected from: H, C.sub.1-6 alkyl, --C(.dbd.NH)NH.sub.2, pyridinyl, pyrimidinyl, (CH.sub.3 O)pyrimidinyl, (CH.sub.3 O).sub.2 pyrimidinyl, oxazolyl, (CH.sub.3)oxazolyl, and (CH.sub.3).sub.2 oxazolyl; R.sup.3, at each occurrence, is selected from: H, C.sub.1-6 alkyl, phenylCH.sub.2 --, and phenylCH.sub.2 CH.sub.2 --; R.sup.AA is, at each occurrence, selected from: H, halo, C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl--, --OH, C.sub.1-4 alkoxy, (C.sub.1-4 alkyl)S--, (C.sub.1-4 alkyl)S(O)--, (C.sub.1-4 alkyl)SO.sub.2 --, --NH.sub.2, (C.sub.1-4 alkyl).sub.2 N--, (C.sub.1-4 alkyl)NH--, --CN, --NO.sub.2, (C.sub.1-4 alkyl)C(.dbd.O)--, HO.sub.2 C--, (C.sub.1-4 alkyl)OC(.dbd.O)--, H.sub.2 NC(.dbd.O)--, (C.sub.1-4 alkyl)NHC(.dbd.O)--, (C.sub.1-4 alkyl)C(.dbd.O)NH--, C.sub.1-4 haloalkyl, and C.sub.1-4 haloalkyloxy; R.sup.B is a 5-10 membered ring system consisting of carbon atoms and 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S; wherein said ring system may be unsaturated, partially unsaturated or saturated; and R.sup.B is substituted with 0, 1, 2, 3, 4, or 5 substituents selected from R.sup.b1, R.sup.b2, R.sup.b3, R.sup.b4, and R.sup.b5 ; alternatively R.sup.B is C.sub.1-4 alkyl substituted with 5-10 membered ring system consisting of carbon atoms and 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S; wherein said ring system may be unsaturated, partially unsaturated or saturated; and R.sup.B is substituted with 0, 1, 2, 3, 4, or 5 substituents selected from R.sup.b1, R.sup.b2, R.sup.b3, R.sup.b4, and R.sup.b5 ; R.sup.b1, R.sup.b2, R.sup.b3, R.sup.b4, and R.sup.b5, at each occurrence, are independently selected from: H, F, Cl, Br, I, .dbd.O, --CN, --NO.sub.2, OR.sup.12, SR.sup.12, NR.sup.12 R.sup.13, C(O)H, C(O)R.sup.12, C(O)OR.sup.12, C(O)NR.sup.12 R.sup.13, OC(O)NR.sup.12 R.sup.13, NR.sup.14 C(O)R.sup.12, OC(O)R.sup.12, CH(.dbd.NR.sup.14)NR.sup.12 R.sup.13, NHC(.dbd.NR.sup.14)NR.sup.12 R.sup.13, S(O)R.sup.12, S(O).sub.2 R.sup.12, S(O)H, S(O).sub.2 H, S(O)NR.sup.12 R.sup.13, S(O).sub.2 NR.sup.12 R.sup.13, NR.sup.14 S(O)R.sup.12, NR.sup.14 S(O).sub.2 R.sup.12, NR.sup.12 C(O)R.sup.15, NR.sup.12 C(O)OR.sup.15, NR.sup.12 S(O).sub.2 R.sup.15, NR.sup.12 C(O)NHR.sup.15, (HO).sub.2 B--, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyloxy, C.sub.2-4 alkynyloxy, (C.sub.1-4 haloalkyl)oxy, C.sub.1-4 alkyl substituted with 0-3 R.sup.11, C.sub.2-4 alkenyl substituted with 0-3 R.sup.11, C.sub.2-4 alkynyl substituted with 0-3 R.sup.11, C.sub.1-4 alkoxy substituted with 0-3 R.sup.11, C.sub.3-10 carbocyclic residue substituted with 0-3 R.sup.31, aryl substituted with 0-5 R.sup.31, and 5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R.sup.31 ; alternatively, R.sup.b1 and R.sup.b2, when substituents on adjacent carbons, or R.sup.b2 and R.sup.b3, when substituents on adjacent carbons, may be combined to form a methylenedioxy group; n is 1, 2, or 3; R.sup.C1, at each occurrence, is independently selected from: H, halo, --CN, --NO.sub.2, OR.sup.12, SR.sup.12, NR.sup.12 R.sup.13, C(O)H, C(O)R.sup.12, C(O)NR.sup.12 R.sup.13, OC(O)NR.sup.12 R.sup.13, NR.sup.14 C(O)R.sup.12, NR.sup.14 C(S)R.sup.12, C(O)OR.sup.12, OC(O)R.sup.12, OC(O)OR.sup.12, CH(.dbd.NR.sup.14)NR.sup.12 R.sup.13, NHC(.dbd.NR.sup.14)NR.sup.12 R.sup.13, S(O)R.sup.12, S(O).sub.2 R.sup.12, S(O)NR.sup.12 R.sup.13, S(O).sub.2 NR.sup.12 R.sup.13, NR.sup.14 S(O)R.sup.12, NR.sup.14 S(O).sub.2 R.sup.12, NR.sup.12 C(O)R.sup.15, NR.sup.12 C(S)R.sup.15, NR.sup.12 C(O)OR.sup.15, NR.sup.12 S(O).sub.2 R.sup.15, NR.sup.12 C(O)NHR.sup.15, C.sub.1-4 haloalkyl, (C.sub.1-4 haloalkyl)oxy, C.sub.1-10 alkyl substituted with 0-3 R.sup.CC, C.sub.2-10 alkenyl substituted with 0-3 R.sup.CC, C.sub.2-10 alkynyl substituted with 0-3 R.sup.CC, C.sub.1-10 alkoxy substituted with 0-3 R.sup.CC, C.sub.3-6 carbocyclic residue substituted with 0-3 R.sup.CC, aryl substituted with 0-5 R.sup.CC, and 5-6 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R.sup.CC ; R.sup.C2 is selected from: H, C.sub.1-4 alkyl, OH, CN, and C.sub.1-4 alkoxy; R.sup.CC, at each occurrence, is independently selected from: H, halo, --CN, --NO.sub.2, OR.sup.12, SR.sup.12, NR.sup.12 R.sup.13, C(O)H, C(O)R.sup.12, C(O)NR.sup.12 R.sup.13, OC(O)NR.sup.12 R.sup.13, NR.sup.14 C(O)R.sup.12, NR.sup.14 C(S)R.sup.12, C(S)NR.sup.12 R.sup.13, C(O)OR.sup.12, OC(O)R.sup.12, OC(O)OR.sup.12, CH(.dbd.NR.sup.14)NR.sup.12 R.sup.13, NHC(.dbd.NR.sup.14)NR.sup.12 R.sup.13, S(O)R.sup.12, S(O).sub.2 R.sup.12, S(O)NR.sup.12 R.sup.13, S(O).sub.2 NR.sup.12 R.sup.13, NR.sup.14 S(O)R.sup.12, NR.sup.14 S(O).sub.2 R.sup.12, NR.sup.12 C(O)R.sup.15, NR.sup.12 C(S)R.sup.15, NR.sup.12 C(O)OR.sup.15, NR.sup.12 S(O).sub.2 R.sup.15, NR.sup.12 C(O)NHR.sup.15, C.sub.1-4 haloalkyl, (C.sub.1-4 haloalkyl)oxy, C.sub.1-4 alkyl substituted with 0-3 R.sup.11, C.sub.2-4 alkenyl substituted with 0-3 R.sup.11, C.sub.2-4 alkynyl substituted with 0-3 R.sup.11, C.sub.1-4 alkoxy substituted with 0-3 R.sup.11, C.sub.3-6 carbocyclic residue substituted with 0-3 R.sup.31, aryl substituted with 0-5 R.sup.31, and 5-6 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R.sup.31 ; ring D, including the two atoms of Ring C to which it is attached, is a phenyl ring; and ring D is substituted with 0-4 R.sup.D ; R.sup.D, at each occurrence, is independently selected from: H, halo, --CN, --NO.sub.2, OR.sup.16, SR.sup.16, NR.sup.16 R.sup.16, C(O)H, C(O)R.sup.16, C(O)NR.sup.16 R.sup.16, OC(O)NR.sup.16 R.sup.16, NR.sup.14 C(O)R.sup.16, C(O)OR.sup.16, OC(O)R.sup.16, OC(O)OR.sup.16, CH(.dbd.NR.sup.14)NR.sup.16 R.sup.16, NHC(.dbd.NR.sup.14)NR.sup.16 R.sup.16, S(O)R.sup.16, S(O).sub.2 R.sup.16, S(O)NR.sup.16 R.sup.16, S(O).sub.2 NR.sup.16 R.sup.16, NR.sup.14 S(O)R.sup.16, NR.sup.14 S(O).sub.2 R.sup.16, NR16C(O)R.sup.17, NR.sup.16 C(O)OR.sup.17, NR.sup.16 S(O).sub.2 R.sup.17, NR.sup.16 C(O)NHR.sup.17, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, (C.sub.1-4 haloalkyl)oxy, C.sub.1-4 alkyl substituted with 0-3 R.sup.31, C.sub.2-4 alkenyl substituted with 0-3 R.sup.31, and C.sub.2-4 alkynyl substituted with 0-3 R.sup.31 ; R.sup.11, at each occurrence, is independently selected from: H, halo, --CN, --NO.sub.2, OR.sup.12, SR.sup.12, NR.sup.12 R.sup.13, C(O)H, C(O)R.sup.12, C(O)NR.sup.12 R.sup.13, OC(O)NR.sup.12 R.sup.13, NR.sup.14 C(O)R.sup.12, C(O)OR.sup.12, OC(O)R.sup.12, OC(O)OR.sup.12, CH(.dbd.NR.sup.14)NR.sup.12 R.sup.13, NHC(.dbd.NR.sup.14)NR.sup.12 R.sup.13, S(O)R.sup.12, S(O).sub.2 R.sup.12, S(O)NR.sup.12 R.sup.13, S(O).sub.2 NR.sup.12 R.sup.13, NR.sup.14 S(O)R.sup.12, NR.sup.14 S(O).sub.2 R.sup.12, NR.sup.12 C(O)R.sup.15, NR.sup.12 C(O)OR.sup.15, NR.sup.12 S(O).sub.2 R.sup.15, NR.sup.12 C(O)NHR.sup.15, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyloxy, C.sub.2-4 alkynyloxy, (C.sub.1-4 haloalkyl)oxy, C.sub.1-4 alkyl substituted with 0-3 R.sup.12a, C.sub.2-4 alkenyl substituted with 0-3 R.sup.12a, C.sub.3-6 carbocyclic residue substituted with 0-3 R.sup.31, aryl substituted with 0-5 R.sup.31, and 5-6 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R.sup.31 ; R.sup.12, at each occurrence, is independently selected from: H, C.sub.1-4 alkyl substituted with 0-1 R.sup.12a, C.sub.2-4 alkenyl substituted with 0-1 R.sup.12a, C.sub.2-4 alkynyl substituted with 0-1 R.sup.12a, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.31, aryl substituted with 0-5 R.sup.31 ; C.sub.3-10 carbocyclic residue substituted with 0-3 R.sup.31, and 5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R.sup.31 ; R.sup.12a, at each occurrence, is independently selected from: phenyl substituted with 0-5 R.sup.31, C.sub.3-6 carbocyclic residue substituted with 0-3 R.sup.31, and 5-6 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R.sup.31 ; R.sup.13, at each occurrence, is independently selected from: H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl; alternatively, R.sup.12 and R.sup.13 may be combined, along with the nitrogen to which they are attached, to form a 5- or 6-membered ring optionally substituted with --O-- or --N(R.sup.14)--; R.sup.14, at each occurrence, is independently selected from: H and C.sub.1-4 alkyl; R.sup.15, at each occurrence, is independently selected from: H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl; R.sup.16, at each occurrence, is independently selected from: H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, and phenyl; R.sup.17, at each occurrence, is independently selected from: H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl; R.sup.31, at each occurrence, is independently selected from: H, F, Cl, Br, I, .dbd.O, --CN, --NO.sub.2, OR.sup.32, SR.sup.32, NR.sup.32 R.sup.33, C(O)H, C(O)R.sup.32, C(O)OH, C(O)OR.sup.32, C(O)NR.sup.32 R.sup.33, OC(O)NR.sup.32 R.sup.33, NR.sup.34 C(O)R.sup.32, OC(O)R.sup.32, CH(.dbd.NR.sup.34)NR.sup.32 R.sup.33, NHC(.dbd.NR.sup.34)NR.sup.32 R.sup.33, S(O)R.sup.32, S(O).sub.2 R.sup.32, S(O)H, S(O).sub.2 H, S(O).sub.3 H, S(O)NR.sup.32 R.sup.33, S(O).sub.2 NR.sup.32 R.sup.33, NR.sup.34 S(O)R.sup.32, NR.sup.34 S(O).sub.2 R.sup.32, NR.sup.32 C(O)R.sup.35, NR.sup.32 C(O)OR.sup.35, NR.sup.32 S(O).sub.2 R.sup.35, NR.sup.32 C(O)NHR.sup.35, tetrazole, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyloxy, C.sub.2-4 alkynyloxy, (C.sub.1-4 haloalkyl)oxy, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, and C.sub.2-4 alkynyl; and R.sup.32, R.sup.33, R.sup.34, R.sup.35, at each occurrence, are independently selected from: H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, and benzyl; provided R.sup.B is phenyl, or chloro-substituted phenyl, then R.sup.A is not chloro, bromo or methoxy. 2. A compound of claim 1, wherein: R.sup.C1 is H, methyl, ethyl, propyl, or butyl; and R.sup.C2 is H or methyl. 3. A compound of claim 1, wherein; R.sup.B is ##STR84## or a stereoisomer or pharmaceutically acceptable salt form thereof. 4. A compound of claim 1 of Formula (Ib): ##STR85## or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein; ring A, including the two atoms of Ring B to which it is attached, is a phenyl ring; wherein, in addition to R.sup.A, ring A is substituted with 0-1 R.sup.AA ; R.sup.A is selected from: Cl, OCH.sub.3, C(.dbd.NH)NH.sub.2, C(O)NH.sub.2, S(O).sub.2 NH.sub.2, --NH.sub.2, --NH.sub.2 NH.sub.3, --CH.sub.2 NH.sub.2, --NR.sup.2 R.sup.3, --CH.sub.2 NR.sup.2 R.sup.3, and --CH(CH.sub.3)NR.sup.2 R.sup.3 ; R.sup.2 is selected from: H and C.sub.1-4 alkyl; R.sup.3 is selected from: H and C.sub.1-4 alkyl; R.sup.AA is H, F, Cl, methoxy, --NH2, or --CH.sub.2 NH.sub.2 ; ring D, including the two atoms of Ring C to which it is attached, is a phenyl ring; and ring D is substituted with 0-2 R.sup.D ; R.sup.D, at each occurrence, is independently selected from: H, halo, --CN, --NO.sub.2, OR.sup.16, SR.sup.16, NR.sup.16 R.sup.16, C(O)H, C(O)R.sup.16, C(O)NR.sup.16 R.sup.16, OC(O)NR.sup.16 R.sup.16, NR.sup.14 C(O)R.sup.16, C(O)OR.sup.16, OC(O)R.sup.16, OC(O)OR.sup.16, CH(.dbd.NR.sup.14)NR.sup.16 R.sup.16, NHC(.dbd.NR.sup.14)NR.sup.16 R.sup.16, S(O)R.sup.16, S(O).sub.2 R.sup.16, S(O)NR.sup.16 R.sup.16, S(O).sub.2 NR.sup.16 R.sup.16, NR.sup.14 S(O)R.sup.16, NR.sup.14 S(O).sub.2 R.sup.16, NR.sup.16 C(O)R.sup.17, NR.sup.16 C(O)OR.sup.17, NR.sup.16 S(O).sub.2 R.sup.17, NR.sup.16 C(O)NHR.sup.17, C.sub.1-3 haloalkyl, (C.sub.1-2 haloalkyl)oxy, C.sub.1-4 alkoxy, and C.sub.1-4 alkyl; R.sup.16, at each occurrence, is independently selected from: H, methyl, and ethyl; and R.sup.17, at each occurrence, is independently selected from: H, methyl, and ethyl. 5. A compound of claim 4 of Formula (Ib) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein; R.sup.A is selected from: --C(.dbd.NH)NH.sub.2, --C(O)NH.sub.2, --S(O).sub.2 NH.sub.2, --NH.sub.2, and --CH.sub.2 NH.sub.2. 6. A compound of claim 4 of Formula (Ic) ##STR86## or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein; R.sup.A is C(.dbd.NH)NH.sub.2 or --CH.sub.2 NH.sub.2 ; and R.sup.B is a 5-10 membered ring system consisting of carbon atoms and 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S; wherein said ring system is selected from phenyl, naphthyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazinyl, thiazolyl, oxazolyl, isoxazolyl, tetrazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, quinolinyl, isoquinolinyl, benzofuranyl, 1H-indazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl, indolyl, chromanyl, benzimidazolyl; and R.sup.B is substituted with 0, 1, 2, 3, 4, or 5 substituents selected from R.sup.b1, R.sup.b2, R.sup.b3, R.sup.b4, and R.sup.b5. 7. A compound of claim 4, wherein; R.sup.A is selected from: --C(.dbd.NH)NH.sub.2, --C(O)NH.sub.2, --S(O).sub.2 NH.sub.2, --NH.sub.2, and --CH.sub.2 NH.sub.2 ; R.sup.B is a 5-10 membered ring system consisting of carbon atoms and 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S; wherein said ring system is selected from phenyl, naphthyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazinyl, thiazolyl, oxazolyl, isoxazolyl, tetrazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyridazinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothienyl, 1H-indazolyl, oxazolidinyl, isoxazolidinyl, benzotriazolyl, benzoxazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, indolyl, chromanyl, benzimidazolyl; and R.sup.B is substituted with 0, 1, 2, 3, 4, or 5 substituents selected from R.sup.b1, R.sup.b2, R.sup.b3, R.sup.b4, R.sup.b5 ; and R.sup.D, at each occurrence, is independently selected from: H, halo, --CN, OH, --COOH, --CONH.sub.2, --CF.sub.3, --SO.sub.2 CH.sub.3, C.sub.1-4 alkoxy, and C.sub.1-4 alkyl. 8. A compound of claim 7, wherein; R.sup.A is C(.dbd.NH)NH.sub.2 or --CH.sub.2 NH.sub.2 ; R.sup.B is a 5-10 membered ring system selected from: phenyl, naphthyl, furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, indolyl, and benzimidazolyl; and R.sup.B is substituted with 0, 1, 2, 3, 4, or 5 substituents selected from R.sup.b1, R.sup.b2, R.sup.b3, R.sup.b4, and R.sup.b5 ; R.sup.b1, R.sup.b2, R.sup.b3, R.sup.b4, and R.sup.b5, at each occurrence, are independently selected from: H, F, Cl, Br, I, .dbd.O, --CN, --NO.sub.2, --OH, OR.sup.12, SR.sup.12, NR.sup.12 R.sup.13, C(O)H, C(O)R.sup.12, C(O)OR.sup.12, C(O)NR.sup.12 R.sup.13, OC(O)NR.sup.12 R.sup.13, NR.sup.14 C(O)R.sup.12, OC(O)R.sup.12, CH(.dbd.NR.sup.14)NR.sup.12 R.sup.13, NHC(.dbd.NR.sup.14)NR.sup.12 R.sup.13, S(O)R.sup.12, S(O).sub.2 R.sup.12, S(O)H, S(O).sub.2 H, S(O)NR.sup.12 R.sup.13, S(O).sub.2 NR.sup.12 R.sub.13, NR.sup.14 S(O)R.sup.12, NR.sup.14 S(O).sub.2 R.sup.12, NR.sup.12 C(O)R.sup.15, NR.sup.12 C(O)OR.sup.15, NR.sup.12 S(O).sub.2 R.sup.15, NR.sup.12 C(O)NHR.sup.15, (HO).sub.2 B--, --CF.sub.3, --OCF.sub.3, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, butyl, C.sub.1-4 alkyl substituted with 0-3 R.sup.11, C.sub.2-4 alkenyl substituted with 0-3 R.sup.11, C.sub.2-4 alkynyl substituted with 0-3 R.sup.11, C.sub.1-4 alkoxy substituted with 0-3 R.sup.11, C.sub.3-6 carbocyclic residue substituted with 0-3 R.sup.31, phenyl substituted with 0-5 R.sup.31, and 5-10 membered heterocyclic ring system selected from furanyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, indolyl, and N-morpholinyl, said heterocyclic ring system substituted with 0-3 R.sup.31 ; alternatively, R.sup.b1 and R.sup.b2, when substituents on adjacent carbons, or R.sup.b2 and R.sup.b3, when substituents on adjacent carbons, may be combined to form a methylenedioxy group; R.sup.D, at each occurrence, is independently selected from: H, F, Cl, Br, --CN, OH, --COOH, --CONH.sub.2, --CF.sub.3, --SO.sub.2 CH.sub.3, methoxy, ethoxy, methyl and ethyl; R.sup.11, at each occurrence, is independently selected from: H, halo, --CN, --NO2, OH, OR.sup.12, SR.sup.12, NR.sup.12 R.sup.13, C(O)H, C(O)R.sup.12, C(O)NR.sup.12 R.sup.13, OC(O)NR.sup.12 R.sup.13, NR.sup.14 C(O)R.sup.12, C(O)OR.sup.12, OC(O)R.sup.12, OC(O)OR.sup.12, CH(.dbd.NR.sup.14)NR.sup.12 R.sup.13, NHC(.dbd.NR.sup.14)NR.sup.12 R.sup.13, S(O)R.sup.12, S(O).sub.2 R.sup.12, S(O)NR.sup.12 R.sup.13, S(O).sub.2 NR.sup.12 R.sup.13, NR.sup.14 S(O)R.sup.12, NR.sup.14 S(O).sub.2 R.sup.12, NR.sup.12 C(O)R.sup.15, NR.sup.12 C(O)OR.sup.15, NR.sup.12 S(O).sub.2 R.sup.15, NR.sup.12 C(O)NHR.sup.15, --CF.sub.3, --OCF.sub.3, methoxy, ethoxy, propoxy, butoxy, C.sub.1-4 alkyl substituted with 0-3 R.sup.12a, C.sub.2-4 alkenyl substituted with 0-3 R.sup.12a, C.sub.3-6 carbocyclic residue substituted with 0-3 R.sup.31, phenyl substituted with 0-5 R.sup.31, and 5-6 membered heterocyclic ring system selected from furanyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, and N-morpholinyl, said heterocyclic ring system substituted with 0-3 R.sup.31 ; R.sup.12, at each occurrence, is independently selected from: H, C.sub.1-4 alkyl substituted with 0-1 R.sup.12a, C.sub.2-4 alkenyl substituted with 0-1 R.sup.12a, C2-4 alkynyl substituted with 0-1 R.sup.12a, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.31, phenyl substituted with 0-5 R.sup.31 ; and 5-6 membered heterocyclic ring system selected from furanyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, pyrazolyl, pyridinyl, and pyrimidinyl, said heterocyclic ring system substituted with 0-3 R.sup.31 ; R.sup.12a, at each occurrence, is independently selected from: phenyl substituted with 0-5 R.sup.31 ; C.sub.3-6 carbocyclic residue substituted with 0-3 R.sup.31, and 5-6 membered heterocyclic ring system selected from furanyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, pyrazolyl, pyridinyl, and pyrimidinyl, said heterocyclic ring system substituted with 0-3 R.sup.31 ; R.sup.13, at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, and butynyl; alternatively, R.sup.12 and R.sup.13 may be combined, along with the nitrogen to which they are attached, to form a 5- or 6-membered ring optionally substituted with --O-- or --N(R.sup.14)--; R.sup.14, at each occurrence, is independently selected from: H, methyl, ethyl, propyl, and butyl; R.sup.15, at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, and butynyl; R.sup.31, at each occurrence, is independently selected from: H, F, Cl, Br, I, .dbd.O, --CN, --NO.sub.2, --OH, --OR.sup.32, --SR.sup.32, --NR.sup.32 R.sup.33, --C(O)H, --C(O)R.sup.32, --C(O)OH, --C(O)OR.sup.32, --C(O)NR.sup.32 R.sup.33, --OC(O)NR.sup.32 R.sup.33, --NR.sup.34 C(O)R.sup.32, --OC(O)R.sup.32, --CH(.dbd.NR.sup.34)NR.sup.32 R.sup.33, --NHC(.dbd.NR.sup.34)NR.sup.32 R.sup.33, --S(O)R.sup.32, --S(O).sub.2 R.sup.32, --S(O)H, --S(O).sub.2 H, --S(O).sub.3 H, --S(O)NR.sup.32 R.sup.33, --S(O).sub.2 NR.sup.32 R.sup.33, --S(O).sub.2 NH.sub.2, --NR.sup.34 S(O)R.sup.32, --NR.sup.34 S(O).sub.2 R.sup.32, --NR.sup.32 C(O)R.sup.35, --NR.sup.32 C(O)OR.sup.35, --NR.sup.32 S(O).sub.2 R.sup.35, --NR.sup.32 C(O)NHR.sup.35, tetrazolyl, --CF.sub.3, --OCF.sub.3, methoxy, ethoxy, n-propoxy, i-propoxy, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, hydroxymethyl-, hydroxyethyl-, vinyl, and allyl; and R.sup.32, R.sup.33, R.sup.34, R.sup.35, at each occurrence, are independently selected from: H, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, and benzyl. 9. A compound of claim 8 wherein: R.sup.b1, R.sup.b2, R.sup.b3, R.sup.b4, and R.sup.b5, at each occurrence, are independently selected from: H, F, Cl, Br, cyano, nitro, methyl, ethyl, n-propyl, i-propyl, vinyl, allyl, hydroxy, hydroxymethyl, hydroxyethyl, hydroxy-n-propyl, hydroxy-i-propyl, methoxy, ethoxy, n-propoxy, i-propoxy, allyloxy-, methyl-S--, ethyl-S--, n-propyl-S--, i-propyl-S--, allyl-S--, --CF.sub.3, --CHF.sub.2, --OCF.sub.3, --SCF.sub.3, --CO.sub.2 H, --C(.dbd.O)OCH.sub.3, --C(.dbd.O)CH.sub.3, --SO.sub.2 CH.sub.3, and --SO.sub.2 CH.sub.2 CH.sub.3. 10. A compound of claim 6 of Formula (Id): ##STR87## or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein; R.sup.A is selected from: Cl, OCH.sub.3, C(.dbd.NH)NH.sub.2, C(O)NH.sub.2, S(O).sub.2 NH.sub.2, --NH.sub.2, and --CH.sub.2 NH.sub.2 ; R.sup.b1, R.sup.b2, R.sup.b3, and R.sup.b4, at each occurrence, are independently selected from: H, F, Cl, Br, I, --CN, --NO.sub.2, --OH, OR.sup.12, SR.sup.12, NR.sup.12 R.sup.13, C(O)H, C(O)R.sup.12, C(O)OR.sup.12, C(O)NR.sup.12 R.sup.13, OC(O)NR.sup.12 R.sup.13, NR.sup.14 C(O)R.sup.12, OC(O)R.sup.12, CH(.dbd.NR.sup.14)NR.sup.12 R.sup.13, NHC(.dbd.NR.sup.14)NR.sup.12 R.sup.13, S(O)R.sup.12, S(O).sub.2 R.sup.12, S(O)H, S(O).sub.2 H, S(O)NR.sup.12 R.sup.13, S(O).sub.2 NR.sup.12 R.sup.13, NR.sup.14 S(O)R.sup.12, NR.sup.14 S(O).sub.2 R.sup.12, NR.sup.12 C(O)R.sup.15, NR.sup.12 C(O)OR.sup.15, NR.sup.12 S(O).sub.2 R.sup.15, NR.sup.12 C(O)NHR.sup.15, (HO).sub.2 B--, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyloxy, C.sub.2-4 alkynyloxy, (C.sub.1-4 haloalkyl)oxy, C.sub.1-4 alkyl substituted with 0-3 R.sup.11, C.sub.2-4 alkenyl substituted with 0-3 R.sup.11, C.sub.2-4 alkynyl substituted with 0-3 R.sup.11, C.sub.1-4 alkoxy substituted with 0-3 R.sup.11, C.sub.3-10 carbocyclic residue substituted with 0-3 R.sup.31, aryl substituted with 0-5 R.sup.31, and 5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R.sup.31 ; and R.sup.b5 is phenyl substituted with 0-5 R.sup.31. 11. A compound of claim 10, wherein; R.sup.b1, R.sup.b2, R.sup.b3, and R.sup.b4, at each occurrence, are independently selected from: H, F, Cl, Br, I, --CN, --NO.sub.2, --OH, OR.sup.12, SR.sup.12, NR.sup.12 R.sup.13, C(O)H, C(O)R.sup.12, C(O)OR.sup.12, C(O)NR.sup.12 R.sup.13, OC(O)NR.sup.12 R.sup.13, NR.sup.14 C(O)R.sup.12, OC(O)R.sup.12, CH(.dbd.NR.sup.14)NR.sup.12 R.sup.13, NHC(.dbd.NR.sup.14)NR.sup.12 R.sup.13, S(O)R.sup.12, S(O).sub.2 R.sup.12, S(O)H, S(O).sub.2 H, S(O)NR.sup.12 R.sup.13, S(O).sub.2 NR.sup.12 R.sup.13, NR.sup.14 S(O)R.sup.12, NR.sup.14 S(O).sub.2 R.sup.12, NR.sup.12 C(O)R.sup.15, NR.sup.12 C(O)OR.sup.15, NR.sup.12 S(O).sub.2 R.sup.15, NR.sup.12 C(O)NHR.sup.15, (HO).sub.2 B--, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, C.sub.2-4 alkenyloxy, C.sub.2-4 alkynyloxy, (C.sub.1-4 haloalkyl)oxy, C.sub.1-4 alkyl substituted with 0-3 R.sup.11, C.sub.2-4 alkenyl substituted with 0-3 R.sup.11, C.sub.2-4 alkynyl substituted with 0-3 R.sup.11, and C.sub.1-4 alkoxy substituted with 0-3 R.sup.11 ; and R.sup.D, at each occurrence, is independently selected from: H, halo, --CN, OH, --COOH, --CONH.sub.2, --CF.sub.3, --SO.sub.2 CH.sub.3, C.sub.1-4 alkoxy, and C.sub.1-4 alkyl. 12. A compound of claim 11, wherein; R.sup.A is C(.dbd.NH)NH.sub.2 or --CH.sub.2 NH.sub.2 ; R.sup.b1, R.sup.b2, R.sup.b3, and R.sup.b4, at each occurrence, are independently selected from: H, F, Cl, Br, I, --CN, --NO.sub.2, --OH, OR.sup.12, SR.sup.12, NR.sup.12 R.sup.13, C(O)H, C(O)R.sup.12, C(O)OR.sup.12, C(O)NR.sup.12 R.sup.13, OC(O)NR.sup.12 R.sup.13, NR.sup.14 C(O)R.sup.12, OC(O)R.sup.12, CH(.dbd.NR.sup.14)NR.sup.12 R.sup.13, NHC(.dbd.NR.sup.14)NR.sup.12 R.sup.13, S(O)R.sup.12, S(O).sub.2 R.sup.12, S(O)H, S(O).sub.2 H, S(O)NR.sup.12 R.sup.13, S(O).sub.2 NR.sup.12 R.sup.13, NR.sup.14 S(O)R.sup.12, NR.sup.14 S(O).sub.2 R.sup.12, NR.sup.12 C(O)R.sup.15, NR.sup.12 C(O)OR.sup.15, NR.sup.12 S(O).sub.2 R.sup.15, NR.sup.12 C(O)NHR.sup.15, (HO).sub.2 B--, --CF.sub.3, --OCF.sub.3, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, butyl, C.sub.1-4 alkyl substituted with 0-3 R.sup.11, C.sub.2-4 alkenyl substituted with 0-3 R.sup.11, C.sub.2-4 alkynyl substituted with 0-3 R.sup.11, and C.sub.1-4 alkoxy substituted with 0-3 R.sup.11 ; R.sup.D, at each occurrence, is independently selected from: H, F, Cl, Br, --CN, OH, --COCH, --CONH.sub.2, --CF.sub.3, --SO2CH.sub.3, methoxy, ethoxy, methyl and ethyl; R.sup.11, at each occurrence, is independently selected from: H, halo, --CN, --NO.sub.2, OH, OR.sup.12, SR.sup.12, NR.sup.12 R.sup.13, C(O)H, C(O)R.sup.12, C(O)NR.sup.12 R.sup.13, OC(O)NR.sup.12 R.sup.13, NR.sup.14 C(O)R.sup.12, C(O)OR.sup.12, OC(O)R.sup.12, OC(O)OR.sup.12, CH(.dbd.NR.sup.14)NR.sup.12 R.sup.13, NHC(.dbd.NR.sup.14)NR.sup.12 R.sup.13, S(O)R.sup.12, S(O).sub.2 R.sup.12, S(O)NR.sup.12 R.sup.13, S(O).sub.2 NR.sup.12 R.sup.13, NR.sup.14 S(O)R.sup.12, NR.sup.14 S(O).sub.2 R.sup.12, NR.sup.12 C(O)R.sup.15, NR.sup.12 C(O)OR.sup.15, NR.sup.12 S(O).sub.2 R.sup.15, NR.sup.12 C(O)NHR.sup.15, --CF.sub.3, --OCF.sub.3, methoxy, ethoxy, propoxy, butoxy, C.sub.1-4 alkyl substituted with 0-3 R.sup.12a, C.sub.2-4 alkenyl substituted with 0-3 R.sup.12a, C.sub.3-6 carbocyclic residue substituted with 0-3 R.sup.31, phenyl substituted with 0-5 R.sup.31, and 5-6 membered heterocyclic ring system selected from furanyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, and N-morpholinyl, said heterocyclic ring system substituted with 0-3 R.sup.31 ; R.sup.12, at each occurrence, is independently selected from: H, C.sub.1-4 alkyl substituted with 0-1 R.sup.12a, C.sub.2-4 alkenyl substituted with 0-1 R.sup.12a, C.sub.2-4 alkynyl substituted with 0-1 R.sup.12a, C.sub.3-6 cycloalkyl substituted with 0-3 R.sup.31, phenyl substituted with 0-5 R.sup.31 ; and 5-6 membered heterocyclic ring system selected from furanyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, pyrazolyl, pyridinyl, and pyrimidinyl, said heterocyclic ring system substituted with 0-3 R.sup.31 ; R.sup.12a, at each occurrence, is independently selected from: phenyl substituted with 0-5 R.sup.31 ; C.sub.3-6 carbocyclic residue substituted with 0-3 R.sup.31, and 5-6 membered heterocyclic ring system selected from furanyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, pyrazolyl, pyridinyl, and pyrimidinyl, said heterocyclic ring system substituted with 0-3 R.sup.31 ; R.sup.13, at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, and butynyl; alternatively, R.sup.12 and R.sup.13 may be combined, along with the nitrogen to which they are attached, to form a 5- or 6-membered ring optionally substituted with --O-- or --N(R.sup.14)--; R.sup.14, at each occurrence, is independently selected from: H, methyl, ethyl, propyl, and butyl; R.sup.15, at each occurrence, is independently selected from: H, methyl, ethyl, propyl, butyl, ethenyl, propenyl, butenyl, ethynyl, propynyl, and butynyl; R.sup.31, at each occurrence, is independently selected from: H, F, Cl, Br, I, --CN, --NO.sub.2, --OH, --OR.sup.32, --SR.sup.32, --NR.sup.32 R.sup.33, --C(O)H, --C(O)R.sup.32, --C(O)OH, --C(O)OR.sup.32, --C(O)NR.sup.32 R.sup.33, --OC(O)NR.sup.32 R.sup.33, --NR.sup.34 C(O)R.sup.32, --OC(O)R.sup.32, --CH(.dbd.NR.sup.34)NR.sup.32 R.sup.33, --NHC(.dbd.NR.sup.34)NR.sup.32 R.sup.33, --S(O)R.sup.32, --S(O).sub.2 R.sup.32, --S(O)H, --S(O).sub.2 H, --S(O).sub.3 H, --S(O)NR.sup.32 R.sup.33, --S(O).sub.2 NR.sup.32 R.sup.33, --S(O).sub.2 NH.sub.2, --NR.sup.34 S(O)R.sup.32, --NR.sup.34 S(O).sub.2 R.sup.32, --NR.sup.32 C(O)R.sup.35, --NR.sup.32 C(O)OR.sup.35, --NR.sup.32 S(O).sub.2 R.sup.35, --NR.sup.32 C(O)NHR.sup.35, tetrazolyl, --CF.sub.3, --OCF.sub.3, methoxy, ethoxy, n-propoxy, i-propoxy, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, hydroxymethyl-, hydroxyethyl-, vinyl, and allyl; and R.sup.32, R.sup.33, R.sup.34, R.sup.35, at each occurrence, are independently selected from: H, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, and benzyl. 13. A compound of claim 12, wherein; n is 1 or 2; and R.sup.b1, R.sup.b2, R.sup.b3, and R.sup.b4, at each occurrence, are independently selected from: H, F, Cl, Br, cyano, nitro, methyl, ethyl, n-propyl, i-propyl, vinyl, allyl, hydroxy, hydroxymethyl, hydroxyethyl, methoxy, ethoxy, n-propoxy, i-propoxy, allyloxy-, methyl-S--, ethyl-S--, n-propyl-S--, i-propyl-S--, allyl-S--, --CF.sub.3, --CHF.sub.2, --OCF.sub.3, --SCF.sub.3, --CO.sub.2 H, --C(.dbd.O)OCH.sub.3, --C(.dbd.O)CH.sub.3, --SO.sub.2 CH.sub.3, and --SO.sub.2 CH.sub.2 CH.sub.3. 14. A compound of claim 12, wherein; n is 1 or 2; R.sup.b1 is selected from: H, F, Cl, Br, cyano, nitro, methyl, ethyl, hydroxy, methoxy, ethoxy, n-propoxy, i-propoxy, allyloxy-, methyl-S--, ethyl-S--, n-propyl-S--, i-propyl-S--, allyl-S--, --CF.sub.3, --CHF.sub.2, --OCF.sub.3, --SCF.sub.3, --SO.sub.2 CH.sub.3, and --SO.sub.2 CH.sub.2 CH.sub.3 ; R.sup.b2 is H, methoxy or ethoxy; R.sup.b3 is hydroxy; R.sup.b4 is selected from: H, F, Cl, Br, cyano, nitro, methyl, ethyl, hydroxy, methoxy, ethoxy, n-propoxy, i-propoxy, allyloxy-, methyl-S--, ethyl-S--, n-propyl-S--, i-propyl-S--, allyl-S--, --CF.sub.3, --CHF.sub.2, --OCF.sub.3, --SCF.sub.3, --SO.sub.2 CH.sub.3, and --SO.sub.2 CH.sub.2 CH.sub.3 ; and R.sup.b5 is phenyl substituted with 0-2 R.sup.31. 15. A compound of claim 12, wherein; n is 1 or 2; R.sup.b1 is selected from: H, F, Cl, Br, cyano, nitro, methyl, ethyl, hydroxy, methoxy, ethoxy, n-propoxy, i-propoxy, allyloxy-, methyl-S--, ethyl-S--, n-propyl-S--, i-propyl-S--, allyl-S--, --CF.sub.3, --CHF.sub.2, --OCF.sub.3, --SCF.sub.3, --SO.sub.2 CH.sub.3, and --SO.sub.2 CH.sub.2 CH.sub.3 ; R.sup.b2 is H, methoxy or ethoxy; R.sup.b3 is hydroxy; R.sup.b4 is selected from: H, F, Cl, Br, cyano, nitro, methyl, ethyl, hydroxy, methoxy, ethoxy, n-propoxy, i-propoxy, allyloxy-, methyl-S--, ethyl-S--, n-propyl-S--, i-propyl-S--, allyl-S--, --CF.sub.3, --CHF.sub.2, --OCF.sub.3, --SCF.sub.3, --SO.sub.2 CH.sub.3, and --SO.sub.2 CH.sub.2 CH.sub.3 ; and R.sup.b5 is phenyl-; 2-chloro-phenyl-; 2-fluoro-phenyl-; 2-cyano-phenyl-; 2-HO.sub.2 C-phenyl-; 2-methyl-phenyl-; 2-ethyl-phenyl-; 2-methoxy-phenyl-; 2-ethoxy-phenyl-; 2-H.sub.3 CS-phenyl-; 2-trifluoromethoxy-phenyl-; 3-fluoro-phenyl-; 3-chloro-phenyl-; 3-HO.sub.2 C-phenyl-; 3-H.sub.2 NCO-phenyl-; 3-cyano-phenyl-; 3-HOCH.sub.2 -phenyl-; 3-H.sub.2 NSO.sub.2 -phenyl-; 3-F.sub.3 C-phenyl-; 3-F.sub.3 CO-phenyl-; 4-methyl-phenyl-; 4-ethyl-phenyl-; 4-i-Pr-phenyl-; 4-i-butyl-phenyl-; 4-t-butyl-phenyl-; 4-MeSO.sub.2 NH-phenyl-; 4-HO.sub.2 C-phenyl-; 4-H.sub.2 NCO-phenyl-; 4-(methyl-NHCO)-phenyl-; 4-(ethyl-NHCO)-phenyl-; 4-(n-propyl-NHCO)-phenyl-; 4-(i-propyl-NHCO)-phenyl-; 4-(i-butyl-NHCO)-phenyl-; 4-methoxy-phenyl-; 4-ethoxy-phenyl-; 4-H.sub.3 CS-phenyl-; 4-trifluoromethoxy-phenyl-; 4-cyano-phenyl-; 4-HOCH.sub.2 -phenyl-; 4-MeSO.sub.2 -phenyl-; 4-H.sub.2 NSO.sub.2 -phenyl-; 4-trifluoromethyl-phenyl-; 4-Me.sub.2 N-phenyl-; 4-tetrazol-5-yl-phenyl-; 2,4-bis-trifluoromethyl-phenyl-; 3,5-difluoro-phenyl-; 2,6-difluoro-phenyl-; 2,4-dichloro-phenyl-; 2,5-dimethoxy-phenyl-; 2,4-dimethoxy-phenyl-; 2,6-dimethoxy-phenyl-; 2-methoxy-4-cyclohexylNHCO-phenyl-; 2-methoxy-4-cyclopentylNHCO-phenyl-; 2-methoxy-4-cyclobutylNHCO-phenyl-; 2-methoxy-4-cyclopropylNHCO-phenyl-; 2-methoxy-4-HO.sub.2 C-phenyl-; 2-methoxy-4-iBuNHCO-phenyl-; 2-methoxy-5-fluoro-phenyl-; 2-methoxy-5-chloro-phenyl-; 2-methoxy-5-methyl-phenyl-; 2-methoxy-5-ethyl-phenyl-; 2-methoxy-5-i-propyl-phenyl-; or 4-(iBu-NHCO)-2-HO.sub.2 C-phenyl-. 16. A compound according to claim 1 wherein; R.sup.B is: ##STR88## or a stereoisomer or pharmaceutically acceptable salt form thereof. 17. A compound according to claim 1 of stereoisomeric Formula (Ie): ##STR89## or pharmaceutically acceptable salt form thereof. 18. A compound according to claim 1 of stereoisomeric Formula (If): ##STR90## or pharmaceutically acceptable salt form thereof. 19. A compound of claim 1 of Formula (I) selected from: 6-(3-chloro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-3-carbo xamidine; 6-(4-hydroxy-3-methoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinol ine-2-carboxamidine; 6-(4-hydroxy-3-ethoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoli ne-2-carboxamidine; 6-(2,3-dimethoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2- carboxamidine; 6-(2,5-dimethoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2- carboxamidine; 6-(2-hydroxy-3-methoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinol ine-2-carboxamidine; 6-(2-hydroxy-5-methoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinol ine-2-carboxamidine; 6-(2,3,4-trimethoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline -2-carboxamidine; 6-(4-methoxy-2,3-dimethyl-phenyl)-5,6a,7,11b-tetrahydro-6H1-indeno[2,1-c]qu inoline-2-carboxamidine; 6-(4-methoxy-2,5-dimethyl-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]qui noline-2-carboxamidine; 6-(3-hydroxy-4-methoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinol ine-2-carboxamidine; 6-(4-methoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-carb oxamidine; 6-(4-hydroxy-3,5-dimethoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]qu inoline-2-carboxamidine; 4-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-ben zoic acid methyl ester; 6-(4-hydroxy-3-methoxy-5-nitro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1- c]quinoline-2-carboxamidine; 6-(3-hydroxy-4,5-dimethoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]qu inoline-2-carboxamidine; 6-(2-hydroxy-3-methoxy-5-nitro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1- c]quinoline-2-carboxamidine; (5-chloro-2-methoxy-phenyl)-carbamic acid 4-(2-carbamimidoyl-5,6a,7,11 b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-2-methoxy-phenyl ester; 6-(6-bromo-2-hydroxy-3-methoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1- c]quinoline-2-carboxamidine; 6-(2-fluoro-5-methoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoli ne-2-carboxamidine; 6-(2-benzyloxy-3-methoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quin oline-2-carboxamidine; 6-(2-fluoro-4-methoxy-phenyl)5,6a7,11b-tetrahydro-6H-indeno[2,1-c]quinoline -2-carboxamidine; 6-(3iodo-4,5-dimethoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinol ine-2-carboxamidine; 6-[2-(2,6dichloro-benzyloxy)-phenyl]-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c] quinoline-2-carboxamidine; 6-[2-(4-chloro-phenylthio)-phenyl-]5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]qu inoline-2-carboxamidine; 6-benzo[1,3]dioxol-4-yl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-c arboxamidine; 6-(2-benzyloxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-ca rboxamidine; 6-(2-allyloxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-car boxamidine; 6-(5-bromo-2-methoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin e-2-carboxamidine; 6-[3-(4-methoxy-phenoxy)-phenyl]-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quin oline-2-carboxamidine; 6-(3,4-dimethoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2- carboxamidine; 6-(4-methanesulfonyl-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin e-2-carboxamidine; 6-[4-(2-hydroxy-ethoxy)-phenyl]-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quino line-2-carboxamidine; 6-(2-chloro-3,4-dimethoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]qui noline-2-carboxamidine; 6-(2-hydroxy-6-methoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinol ine-2-carboxamidine; 3-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-ben zoic acid methyl ester; 5-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-2-m ethoxybenzeneboronic acid; 6-(3-bromo-4-hydroxy-5-methoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1- c]quinoline-2-carboxamidine; 6-pentafluorophenyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-carbo xamidine; 6-(2,4-dichloro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-c arboxamidine; 6-(2-chloro-6-fluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin e-2-carboxamidine; 6-(3,4-dichloro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-c arboxamidine; 6-(3,5-dichloro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-c arboxamidine; 6-[3-(3,5-dichloro-phenoxy)-phenyl]-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]q uinoline-2-carboxamidine; 6-(3-benzyloxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-ca rboxamidine; 6-(3-trifluoromethyl-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin e-2-carboxamidine; 6-(4-bromo-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-carbox amidine; 6-(4-fluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-carbo xamidine; 6-(4-chloro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-carbo xamidine; 6-(4-ethoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-carbo xamidine; 6-(4-methoxy-naphthalen-1-yl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoli ne-2-carboxamidine; 6-(4-trifluoromethyl-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin e-2-carboxamidine; 6-(2,3-difluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-c arboxamidine; 6-(2,4-difluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-c arboxamidine; 6-(2,5-difluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-c arboxamidine; 6-(3,4-difluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-c arboxamidine; 6-(3-chloro-4-fluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin e-2-carboxamidine; 6-(4-pyrrolidin-1-yl-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin e-2-carboxamidine; 6-(5-bromo-2-ethoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline -2-carboxamidine; 6-(4-trifluoromethoxy-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoli ne-2-carboxamidine; 6-(4-propyl-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-carbo xamidine; 6-(3-bromo-4-fluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline -2-carboxamidine; 6-(2,2-dimethyl-chroman-6-yl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoli ne-2-carboxamidine; 6-(2,3,6-trifluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline- 2-carboxamidine; 6-(2,4,5-trifluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline- 2-carboxamidine; 6-(2,4,6-trifluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline- 2-carboxamidine; 6-(2,3,4-trifluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline- 2-carboxamidine; 6-(2-fluoro-3-trifluoromethyl-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c ]quinoline-2-carboxamidine; 6-(2-fluoro-6-trifluoromethyl-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c ]quinoline-2-carboxamidine; 6-(3-fluoro-5-trifluoromethyl-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c ]quinoline-2-carboxamidine; 6-(4-fluoro-2-trifluoromethyl-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c ]quinoline-2-carboxamidine; 6-(2,3,5-trifluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline- 2-carboxamidine; 6-[2-(4-tert-butyl-phenoxy)-5-nitro-phenyl]-5,6a,7,11b-tetrahydro-6H-indeno [2,1-c]quinoline-2-carboxamidine; 6-(2-chloro-5-trifluoromethyl-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c ]quinoline-2-carboxamidine; 6-(4-chloro-2-fluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin e-2-carboxamidine; 6-(4-chloro-3-fluoro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin e-2-carboxamidine; 6-(2-benzylmercapto-5-nitro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]q uinoline-2-carboxamidine; 6-(2-morpholin-4-yl-5-nitro-phenyl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]q uinoline-2-carboxamidine; 6-(3-phenyl-1H-pyrazol-4-yl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin e-2-carboxamidine; 6-(2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-5,6a,7,11b-tetrahydro-6H-in deno[2,1-c]quinoline-2-carboxamidine; 6-(2-phenyl-1H-imidazol-4-yl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoli ne-2-carboxamidine; 6-(1H-imidazol-4-yl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-carb oxamidine; 6-(5-methyl-1H-pyrazol-4-yl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin e-2-carboxamidine; 6-thiophen-2-yl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-carboxami dine; 6-[5-(3-trifluoromethyl-phenyl)-furan-2-yl]-5,6a,7,11b-tetrahydro-6H-indeno [2,1-c]quinoline-2-carboxamidine; 6-[5-(2-chloro-phenyl)-furan-2-yl]-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]qu inoline-2-carboxamidine; 6-[5-(2,5-dichloro-phenyl)-furan-2-yl]-5,6a,7,11b-tetrahydro-6H-indeno[2,1- c]quinoline-2-carboxamidine; 6-[5-(2-trifluoromethoxy-phenyl)-furan-2-yl]-5,6a,7,11b-tetrahydro-6H-inden o[2,1-c]quinoline-2-carboxamidine; 6-(4,5-dibromo-thiophen-2-yl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoli ne-2-carboxamidine; 6-[5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophen-2-yl]-5,6a,7,11b -tetrahydro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(3-phenoxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridine-3-carb oxamidine; 6-(2-chloro-4-fluoro-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin e-2-carboxamidine; 6-(4-hydroxy-3-methoxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthrid ine-2-carboxamidine; 6-(3,5-dibromo-4-hydroxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthr idine-2-carboxamidine; 6-(3,5-dimethoxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridine-2- carboxamidine; 6-(2-hydroxy-3-methoxy-5-nitro-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phe nanthridine-2-carboxamidine; acetic acid 4-(2-carbamimidoyl-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin-6-yl)-2- methoxy-phenyl ester 6-(5-bromo-2-methoxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin e-2-carboxamidine; 6-(2-fluoro-5-methoxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridi ne-2-carboxamidine; 3-(2-carbamimidoyl-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin-6-yl)-ben zoic acid methyl ester; 6-(2-benzyloxy-3-methoxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthr idine-2-carboxamidine; 6-(2-fluoro-4-methoxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridi ne-2-carboxamidine; 6-(4-methanesulfonyl-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin e-2-carboxamidine; 6-(2-benzyloxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridine-2-ca rboxamidine; 6-benzo[1,3]dioxol-4-yl-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridine-2-c arboxamidine; 6-(3-trifluoromethyl-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin e-2-carboxamidine; 6-(2-morpholin-4-yl-5-nitro-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenan thridine-2-carboxamidine; 6-(4-hydroxy-naphthalen-1-yl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridi ne-2-carboxamidine; N-[4-(2-carbamimidoyl-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin-6-yl)- phenyl]-acetamide; 6-(4-hydroxy-3-iodo-5-methoxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phen anthridine-2-carboxamidine; 6-(3-bromo-4-hydroxy-5-methoxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phe nanthridine-2-carboxamidine; 6-(3-ethoxy-4-hydroxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridi ne-2-carboxamidine; 6-(4-hydroxy-3,5-dimethyl-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanth ridine-2-carboxamidine; 6-(4-hydroxy-3,5-dimethoxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenant hridine-2-carboxamidine; 6-(3-fluoro-4-hydroxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridi ne-2-carboxamidine; 6-(4-hydroxy-3-methyl-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridi ne-2-carboxamidine; 6-(2-chloro-4-hydroxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridi ne-2-carboxamidine; 4-(2-carbamimidoyl-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin-6-yl)-ben zoic acid; 6-phenethyl-5,6,6a,7,8,12b-hexahydro-benzo[k]-phenanthridine-2-carboxamidin e; 6-(3,4-dimethyl-thieno[2,3-b]thiophen-2-yl)-5,6,6a,7,8,12b-hexahydro-benzo[ k]phenanthridine-2-carboxamidine; 6-(4-phenylethynyl-thiophen-2-yl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanth ridine-2-carboxamidine; 6-(3-phenoxy-thiophen-2-yl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridine -2-carboxamidine; 6-3-(2-carbamimidoyl-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin-6-yl)-1 H-indole-6-carboxylic acid methyl ester; 6-[5-(2-trifluoromethoxy-phenyl)-furan-2-yl]-5,6,6a,7,8,12b-hexahydro-benzo [k]phenanthridine-2-carboxamidine; 6-(4-bromo-thiophen-2-yl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridine-2 -carboxamidine; 6-(5-methyl-thiophen-2-yl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridine- 2-carboxamidine; 6-(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)-5,6,6a,7,8,12b-hexahydro-benzo[k]ph enanthridine-2-carboxamidine; 6-[5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophen-2-yl]-5,6,6a,7,8 ,12b-hexahydro-benzo[k]phenanthridine-2-carboxamidine; 6-(5-phenylethynyl-thiophen-2-yl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanth ridine-2-carboxamidine; 6-(1-methyl-1H-benzoimidazol-2-yl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenant hridine-2-carboxamidine; 6-[5-(4-sulfamoyl-phenyl)-furan-2-yl]-5,6,6a,7,8,12b-hexahydro-benzo[k]phen anthridine-2-carboxamidine; 6-[5-(2-chloro-phenyl)-furan-2-yl]-5,6,6a,7,8,12b-hexahydro-benzo[k]phenant hridine-2-carboxamidine; 6-(1-methyl-3-phenyl-5-p-tolylsulfanyl-1H-pyrazol-4-yl)-5,6,6a,7,8,12b-hexa hydro-benzo[k]phenanthridine-2-carboxamidine; 6-[5-(2-trifluoromethyl-phenyl)-furan-2-yl]-5,6,6a,7,8,12b-hexahydro-benzo[ k]phenanthridine-2-carboxamidine; 6-(4-bromo-furan-2-yl)-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridine-2-ca rboxamidine; 6-[2,2']bithiophenyl-5-yl-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridine-2 -carboxamidine; 6-[4-(2-cyano-thiophen-3-ylmethoxy)-phenyl]-5,6,6a,7,8,12b-hexahydro-benzo[ k]phenanthridine-2-carboxamidine; 6-[1-(4-chloro-phenyl)-1H-pyrrol-2-yl]-5,6,6a,7,8,12b-hexahydro-benzo[k]phe nanthridine-2-carboxamidine; 6-(2,3-dibromo-4-hydroxy-5-methoxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k ]phenanthridine-2-carboxamidine; [4-(2-carbamimidoyl-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin-6-yl)-2- methoxy-phenoxy]-acetic acid; 6-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-5,6,6a,7,8,12b-hexahydro-benz o[k]phenanthridine-2-carboxamidine; 6-(4-hydroxy-3-methoxy-phenyl)-5,6a,7,8,9,13b-hexahydro-6H-5-aza-benzo[6,7] cyclohepta[1,2-a]naphthalene-2-carboxamidine; 6-(5-hydroxy-4'-isopropyl-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H -indeno[2,1-c]quinoline-2-carboxamidine; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-4'-methoxy-biphenyl-4-carboxylic acid; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-4'-methoxy-biphenyl-4-carboxylic acid isobutyl-amide; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-4'-methoxy-biphenyl-2-carboxylic acid; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-4'-methoxy-biphenyl-3-carboxylic acid; 6-(5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c ]quinoline-2-carboxamidine; 6-(5-hydroxy-4,2'-dimethoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-indeno[ 2,1-c]quinoline-2-carboxamidine; 6-(4'-ethoxy-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-in deno[2,1-c]quinoline-2-carboxamidine; 6-(3'-cyano-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-ind eno[2,1-c]quinoline-2-carboxamidine; 6-(4'-cyano-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-ind eno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-3'-hydroxymethyl-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydr o-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4'-methanesulfonylamino-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-te trahydro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4'-methanesulfonyl-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahy dro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4'-hydroxymethyl-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydr o-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(4-hydroxy-5-methoxy-2-pyridin-3-yl-phenyl)-5,6a,7,11b-tetrahydro-6H-inde no[2,1-c]quinoline-2-carboxamidine; 6-[2-(2,4-dimethoxy-pyrimidin-5-yl)-4-hydroxy-5-methoxy-phenyl]-5,6a,7,11b- tetrahydro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-4-isobutylcarbamoyl-4'-methoxy-biphenyl-2-carboxylic acid benzyl ester; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-4-isobutylcarbamoyl-4'-methoxy-biphenyl-2-carboxylic acid; 6'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-3' -hydroxy-2',4'-dimethoxy-biphenyl-2-carboxylic acid; 2'-(2-carbamimidoyl-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin-6-yl)-5' -hydroxy-4'-methoxy-biphenyl-3-carboxylic acid; 2'-(2-carbamimidoyl-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin-6-yl)-5' -hydroxy-4'-methoxy-biphenyl-4-carboxylic acid; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-4'-methoxy-biphenyl-3-carboxylic acid amide; 6-(5-hydroxy-4-methoxy-4'-sulfamoyl-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H -indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4-methoxy-3'-sulfamoyl-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H -indeno[2,1-c]quinoline-2-carboxamidine; 2'-(2-carbamimidoyl-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin-6-yl)-5' -hydroxy-4'-methoxy-biphenyl-2-carboxylic acid; 6'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-3' -hydroxy-2',4'-dimethoxy-biphenyl-3-carboxylic acid; 6'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-3' -hydroxy-2',4'-dimethoxy-biphenyl-4-carboxylic acid; 6-(4-hydroxy-5-methoxy-2-thiophen-3-yl-phenyl)-5,6a,7,11b-tetrahydro-6H-ind eno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4,2',5'-trimethoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-ind eno[2,1-c]quinoline-2-carboxamidine; 6-(2'-chloro-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-in deno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4,2',6'-trimethoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-ind eno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4-methoxy-2'-methylsulfanyl-biphenyl-2-yl)-5,6a,7,11b-tetrahyd ro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4-methoxy-[1,1'; 2',1"]terphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-ca rboxamidine; 6-(5'-fluoro-5-hydroxy-4,2'-dimethoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro- 6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(2',4'-dichloro-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro- 6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(2',6'-difluoro-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro- 6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4-methoxy-3'-trifluoromethoxy-biphenyl-2-yl)-5,6a,7,11b-tetrah ydro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(3'-chloro-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-in deno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4-methoxy-4'-methylsulfanyl-biphenyl-2-yl)-5,6a,7,11b-tetrahyd ro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4-methoxy-2'-methyl-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-in deno[2,1-c]quinoline-2-carboxamidine; 6-[2-(5-chloro-thiophen-2-yl)-4-hydroxy-5-methoxy-phenyl]-5,6a,7,11b-tetrah ydro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-5'-isopropyl-4,2'-dimethoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahyd ro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4-methoxy-4'-trifluoromethyl-biphenyl-2-yl)-5,6a,7,11b-tetrahy dro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4-methoxy-3'-trifluoromethyl-biphenyl-2-yl)-5,6a,7,11b-tetrahy dro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4,4'-dimethoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-indeno[ 2,1-c]quinoline-2-carboxamidine; 6-(2'-fluoro-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-in deno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4,2',4'-trimethoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-ind eno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4-methoxy-[1,1'; 3',1"]terphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinoline-2-ca rboxamidine; 6-(5'-chloro-5-hydroxy-4,2'-dimethoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro- 6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(4'-dimethylamino-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydr o-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-[4-hydroxy-5-methoxy-2-(6-methoxy-pyridin-3-yl)-phenyl]-5,6a,7,11b-tetrah ydro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(4'-benzyloxy-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H -indeno[2,1-c]quinoline-2-carboxamidine; 6-(4'-tert-butyl-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6 H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4,2'-dimethoxy-5'-methyl-biphenyl-2-yl)-5,6a,7,11b-tetrahydro- 6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4'-isobutyl-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H- indeno[2,1-c]quinoline-2-carboxamidine; 6-(2'-ethoxy-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-in deno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4-methoxy-2'-trifluoromethoxy-biphenyl-2-yl)-5,6a,7,11b-tetrah ydro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(2'-benzyloxy-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H -indeno[2,1-c]quinoline-2-carboxamidine; 6-(2'-ethyl-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-ind eno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4-methoxy-4'-phenoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro-6H-i ndeno[2,1-c]quinoline-2-carboxamidine; 6-(5-hydroxy-4-methoxy-2',4'-bis-trifluoromethyl-biphenyl-2-yl)-5,6a,7,11b- tetrahydro-6H-indeno[2,1-c]quinoline-2-carboxamidine; [2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5 '-hydroxy-4'-methoxy-biphenyl-4-yl]-carbamic acid benzyl ester; 6-(5-hydroxy-4-methoxy-4'-trifluoromethoxy-biphenyl-2-yl)-5,6a,7,11b-tetrah ydro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 6-(3',5'-difluoro-5-hydroxy-4-methoxy-biphenyl-2-yl)-5,6a,7,11b-tetrahydro- 6H-indeno[2,1-c]quinoline-2-carboxamidine; 4-[2-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)- 5-hydroxy-4-methoxy-phenoxy]-benzoic acid; 3-[2-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)- 5-hydroxy-4-methoxy-phenoxy]-benzoic acid; 4-[5-benzyloxy-2-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]qui nolin-6-yl)-4-methoxy-phenoxy]-benzoic acid; 3-[5-benzyloxy-2-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]qui nolin-6-yl)-4-methoxy-phenoxy]-benzoic acid; 4-(2-aminomethyl-5,6,6a,7,8,12b-hexahydro-benzo[k]phenanthridin-6-yl)-2-met hoxy-phenol; 2'-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5'-h ydroxy-4'-methoxy-biphenyl-2-carboxylic acid; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-4'-methoxy-biphenyl-4-carboxylic acid amide; 9-hydroxy-6-(4-hydroxy-3-methoxy-phenyl)-5,6,6a,7,8,12b-hexahydro-benzo[k]p henanthridine-2-carboxamidine; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-4,2'- dimethoxy-biphenyl-3-ol; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-4,2'- dimethoxy-5'-methyl-biphenyl-3-ol; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-4-met hoxy-2'-methylsulfanyl-biphenyl-3-ol; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-2'-fl uoro-4-methoxy-biphenyl-3-ol; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5'-fl uoro-4,2'-dimethoxy-biphenyl-3-ol; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5'-ch loro-4,2'-dimethoxy-biphenyl-3-ol; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-2'-et hoxy-4-methoxy-biphenyl-3-ol; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-2'-et hyl-4-methoxy-biphenyl-3-ol; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-4-met hoxy-2'-trifluoromethoxy-biphenyl-3-ol; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-2'-be nzyloxy-4-methoxy-biphenyl-3-ol; N-[2'-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5 '-hydroxy-4'-methoxy-biphenyl-4-yl]-methanesulfonamide; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-4,2', 4'-trimethoxy-biphenyl-3-ol; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-2',6' -difluoro-4-methoxy-biphenyl-3-ol; 2'-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5'-h ydroxy-4'-methoxy-biphenyl-3-carboxylic acid; 2'-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5'-h ydroxy-2,4'-dimethoxy-biphenyl-4-carboxylic acid; 4-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-2-met hoxy-5-(2-methoxy-phenoxy)-phenol; 6-(2-aminomethyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-4,2', 6'-trimethoxy-biphenyl-3-ol; 6-[5-hydroxy-4-methoxy-4'-(1H-tetrazol-5-yl)-biphenyl-2-yl]-5,6a,7,11b-tetr ahydro-6H-indeno[2,1-c]quinoline-2-carboxamidine; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-2,4'-dimethoxy-biphenyl-4-carboxylic acid; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-2,4'-dimethoxy-biphenyl-4-carboxylic acid isobutyl-amide; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-2,4'-dimethoxy-biphenyl-4-carboxylic acid benzylamide; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-2,4'-dimethoxy-biphenyl-4-carboxylic acid (2-morpholin-4-yl-ethyl)-amide; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-2,4'-dimethoxy-biphenyl-4-carboxylic acid cyclohexylamide; 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-2,4'-dimethoxy-biphenyl-4-carboxylic acid cyclopropylamide; and 2'-(2-carbamimidoyl-5,6a,7,11b-tetrahydro-6H-indeno[2,1-c]quinolin-6-yl)-5' -hydroxy-2,4'-dimethoxy-biphenyl-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide; or a stereoisomer or pharmaceutically acceptable salt form thereof. 20. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof. 21. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof. 22. A method according to claim 21, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart. 23. A method according to claim 21, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis. 24. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a first and second therapeutic agent, wherein the first therapeutic agent is compound of claim 1 or a pharmaceutically acceptable salt thereof and the second therapeutic agent is at least one agent selected from a second factor VIIa inhibitor, an anti-coagulant agent, an anti-platelet agent, a thrombin inhibiting agent, a thrombolytic agent, and a fibrinolytic agent. 25. A method according to claim 24, wherein the second therapeutic agent is at least one agent selected from warfarin, unfractionated heparin, low molecular weight heparin, synthetic pentasaccharide, hirudin, argatrobanas, aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, piroxicam, ticlopidine, clopidogrel, tirofiban, eptifibatide, abciximab, melagatran, disulfatohirudin, tissue plasminogen activator, modified tissue plasminogen activator, anistreplase, urokinase, and streptokinase. 26. The method according to claim 24, wherein the second therapeutic agent is at least one anti-platelet agent. 27. The method according to claim 26, wherein the anti-platelet agent is aspirin and clopidogrel. 28. The method according to claim 26, wherein the anti-platelet agent is clopidogrel. 29. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 19 or a pharmaceutically acceptable salt form thereof. 30. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 19 or a pharmaceutically acceptable salt form thereof. 31. A method according to claim 30, wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart. 32. A method according to claim 30, wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, first myocardial infarction, recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophiebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promotes thrombosis. 33. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a first and second therapeutic agent, wherein the first therapeutic agent is compound of claim 19 or a pharmaceutically acceptable salt thereof and the second therapeutic agent is at least one agent selected from a second factor VIIa inhibitor, an anti-coagulant agent, an anti-platelet agent, a thrombin inhibiting agent, a thrombolytic agent, and a fibrinolytic agent. 34. A method according to claim 33, wherein the second therapeutic agent is at least one agent selected from warfarin, unfractionated heparin, low molecular weight heparin, synthetic pentasaccharide, hirudin, argatrobanas, aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, piroxicam, ticlopidine, clopidogrel, tirofiban, eptifibatide, abciximab, melagatran, disulfatohirudin, tissue plasminogen activator, modified tissue plasminogen activator, anistreplase, urokinase, and streptokinase. 35. The method according to claim 33, wherein the second therapeutic agent is at least one anti-platelet agent. 36. The method according to claim 35, wherein the anti-platelet agent is aspirin and clopidogrel. 37. The method according to claim 35, wherein the anti-platelet agent is clopidogrel.

Details for Patent 6,825,208

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2021-08-20
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2021-08-20